Thomas E. Goodwin
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Researcher
Also affiliated: Australian National University (2006); CSIRO Oceans and Atmosphere (2012); University of Minnesota (1998); United States Bureau of Reclamation (1973); Oregon Health & Science University (2002); University of Oregon (2009); Wright State University (1998); St. Olaf College (2009); AdventHealth Lake Placid (1995); Georgia Southern University (2007); Xerox (United States) (1998); Conway School of Landscape Design (1981–2026); University of Rochester (1998); Rice University (1977); Texas A&M University (1978–1981); Technische Universität Braunschweig (2002)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Thomas E. Goodwin's research program focuses on cancer therapy, specifically investigating novel drug targets and combination therapies for hematological malignancies and solid tumors. He has published work on dihydroorotate dehydrogenase (DHODH) inhibitors, such as Hosu-53, examining their efficacy as monotherapies and in augmenting targeted treatments like CD47 blockade in acute myeloid leukemia (AML) and multiple myeloma. His work also explores the impact of DHODH inhibition on T cell metabolism, particularly in the context of graft-versus-host disease (GvHD) and graft-versus-leukemia (GvL) responses following hematopoietic stem cell transplantation.
In addition to his work on cancer therapeutics, Goodwin has also investigated animal communication, specifically studying how olfactory cues encode identity and group membership in African elephants. This research utilizes analytical techniques such as gas chromatography-mass spectrometry. His scholarly output includes over 100 publications and he holds an h-index of 22 with over 1,400 citations, reflecting a highly cited researcher designation. Goodwin leads a research group and collaborates with other researchers at Hendrix College.
Metrics
- h-index: 22
- Publications: 107
- Citations: 1,500
Selected Publications
-
Abstract 7905: Dihydroorotate dehydrogenase (DHODH) inhibition as a promising therapeutic strategy with synergistic targeting of ROR1 in small cell lung cancer (2026)
-
Abstract 6902: Promising therapeutic effects of pyrimidine synthesis inhibition by a novel dihydroorotate dehydrogenase inhibitor in small cell lung cancer (2025)
-
DHODH inhibition alters T cell metabolism limiting acute graft-versus<i>-</i>host disease while retaining <i>graft-</i>versus<i>-</i>leukemia response (2025)
-
DHODH Inhibition Modulates T Cell Metabolism, Selectively Impairs Effector T Cell Response, Limiting Gvhd While Preserving GVL. (2025)
-
Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia (2024)
-
The Potent Dihydroorotate Dehydrogenase Inhibitor, Hosu-53, Exhibits Compelling Monotherapy Efficacy in Multiple Myeloma and Augments CD47 Targeted Therapy (2023)
-
Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor Accentuates CD47 Blockade Therapy Resulting in Long Term Survival in Acute Myeloid Leukemia (2022)
-
Preclinical Development of Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor with Impressive Single Agent Efficacy and Combination Approaches in Hematological Malignancy (2022)
-
A pachyderm perfume: odour encodes identity and group membership in African elephants (2022)
-
Abstract 1060: Introducing a novel DHODH inhibitor with superior <i>in vivo</i> activity as monotherapy or in novel combination regimen with immunotherapy for hematological malignancies (2022)
-
Learning Organic Chemistry from Bark Beetle Pheromone Biosynthesis (2019)
-
P-Mail: The Information Highway of Nocturnal, but Not Diurnal or Cathemeral, Strepsirrhines (2019)
-
Concentration‐dependent chemosensory responses towards pheromones are influenced by receiver attributes in Asian elephants (2018)
-
Stereospecific Metabolism of R- and S-Warfarin by Human Hepatic Cytosolic Reductases (2017)
-
Reproductive endocrine patterns and volatile urinary compounds of Arctictis binturong: discovering why bearcats smell like popcorn (2016)
Collaboration Network
Top Collaborators
- Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia
- The Potent Dihydroorotate Dehydrogenase Inhibitor, Hosu-53, Exhibits Compelling Monotherapy Efficacy in Multiple Myeloma and Augments CD47 Targeted Therapy
- Preclinical Development of Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor with Impressive Single Agent Efficacy and Combination Approaches in Hematological Malignancy
- Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor Accentuates CD47 Blockade Therapy Resulting in Long Term Survival in Acute Myeloid Leukemia
- DHODH Inhibition Modulates T Cell Metabolism, Selectively Impairs Effector T Cell Response, Limiting Gvhd While Preserving GVL.
Showing 5 of 7 shared publications
- The Potent Dihydroorotate Dehydrogenase Inhibitor, Hosu-53, Exhibits Compelling Monotherapy Efficacy in Multiple Myeloma and Augments CD47 Targeted Therapy
- Preclinical Development of Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor with Impressive Single Agent Efficacy and Combination Approaches in Hematological Malignancy
- Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor Accentuates CD47 Blockade Therapy Resulting in Long Term Survival in Acute Myeloid Leukemia
- DHODH Inhibition Modulates T Cell Metabolism, Selectively Impairs Effector T Cell Response, Limiting Gvhd While Preserving GVL.
- DHODH inhibition alters T cell metabolism limiting acute graft-versus<i>-</i>host disease while retaining <i>graft-</i>versus<i>-</i>leukemia response
Showing 5 of 6 shared publications
- The Potent Dihydroorotate Dehydrogenase Inhibitor, Hosu-53, Exhibits Compelling Monotherapy Efficacy in Multiple Myeloma and Augments CD47 Targeted Therapy
- Preclinical Development of Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor with Impressive Single Agent Efficacy and Combination Approaches in Hematological Malignancy
- Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor Accentuates CD47 Blockade Therapy Resulting in Long Term Survival in Acute Myeloid Leukemia
- DHODH Inhibition Modulates T Cell Metabolism, Selectively Impairs Effector T Cell Response, Limiting Gvhd While Preserving GVL.
- DHODH inhibition alters T cell metabolism limiting acute graft-versus<i>-</i>host disease while retaining <i>graft-</i>versus<i>-</i>leukemia response
Showing 5 of 6 shared publications
- Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia
- The Potent Dihydroorotate Dehydrogenase Inhibitor, Hosu-53, Exhibits Compelling Monotherapy Efficacy in Multiple Myeloma and Augments CD47 Targeted Therapy
- Preclinical Development of Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor with Impressive Single Agent Efficacy and Combination Approaches in Hematological Malignancy
- Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor Accentuates CD47 Blockade Therapy Resulting in Long Term Survival in Acute Myeloid Leukemia
- DHODH inhibition alters T cell metabolism limiting acute graft-versus<i>-</i>host disease while retaining <i>graft-</i>versus<i>-</i>leukemia response
Showing 5 of 6 shared publications
- Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia
- The Potent Dihydroorotate Dehydrogenase Inhibitor, Hosu-53, Exhibits Compelling Monotherapy Efficacy in Multiple Myeloma and Augments CD47 Targeted Therapy
- Preclinical Development of Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor with Impressive Single Agent Efficacy and Combination Approaches in Hematological Malignancy
- Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor Accentuates CD47 Blockade Therapy Resulting in Long Term Survival in Acute Myeloid Leukemia
- The Potent Dihydroorotate Dehydrogenase Inhibitor, Hosu-53, Exhibits Compelling Monotherapy Efficacy in Multiple Myeloma and Augments CD47 Targeted Therapy
- Preclinical Development of Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor with Impressive Single Agent Efficacy and Combination Approaches in Hematological Malignancy
- Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor Accentuates CD47 Blockade Therapy Resulting in Long Term Survival in Acute Myeloid Leukemia
- Abstract 6902: Promising therapeutic effects of pyrimidine synthesis inhibition by a novel dihydroorotate dehydrogenase inhibitor in small cell lung cancer
- Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia
- Preclinical Development of Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor with Impressive Single Agent Efficacy and Combination Approaches in Hematological Malignancy
- Abstract 6902: Promising therapeutic effects of pyrimidine synthesis inhibition by a novel dihydroorotate dehydrogenase inhibitor in small cell lung cancer
- Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia
- The Potent Dihydroorotate Dehydrogenase Inhibitor, Hosu-53, Exhibits Compelling Monotherapy Efficacy in Multiple Myeloma and Augments CD47 Targeted Therapy
- Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor Accentuates CD47 Blockade Therapy Resulting in Long Term Survival in Acute Myeloid Leukemia
- Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia
- The Potent Dihydroorotate Dehydrogenase Inhibitor, Hosu-53, Exhibits Compelling Monotherapy Efficacy in Multiple Myeloma and Augments CD47 Targeted Therapy
- Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor Accentuates CD47 Blockade Therapy Resulting in Long Term Survival in Acute Myeloid Leukemia
- Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia
- Preclinical Development of Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor with Impressive Single Agent Efficacy and Combination Approaches in Hematological Malignancy
- The Potent Dihydroorotate Dehydrogenase Inhibitor, Hosu-53, Exhibits Compelling Monotherapy Efficacy in Multiple Myeloma and Augments CD47 Targeted Therapy
- Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor Accentuates CD47 Blockade Therapy Resulting in Long Term Survival in Acute Myeloid Leukemia
- DHODH Inhibition Modulates T Cell Metabolism, Selectively Impairs Effector T Cell Response, Limiting Gvhd While Preserving GVL.
- DHODH inhibition alters T cell metabolism limiting acute graft-versus<i>-</i>host disease while retaining <i>graft-</i>versus<i>-</i>leukemia response
- DHODH Inhibition Modulates T Cell Metabolism, Selectively Impairs Effector T Cell Response, Limiting Gvhd While Preserving GVL.
- DHODH inhibition alters T cell metabolism limiting acute graft-versus<i>-</i>host disease while retaining <i>graft-</i>versus<i>-</i>leukemia response
- DHODH Inhibition Modulates T Cell Metabolism, Selectively Impairs Effector T Cell Response, Limiting Gvhd While Preserving GVL.
- DHODH inhibition alters T cell metabolism limiting acute graft-versus<i>-</i>host disease while retaining <i>graft-</i>versus<i>-</i>leukemia response
- DHODH Inhibition Modulates T Cell Metabolism, Selectively Impairs Effector T Cell Response, Limiting Gvhd While Preserving GVL.
- DHODH inhibition alters T cell metabolism limiting acute graft-versus<i>-</i>host disease while retaining <i>graft-</i>versus<i>-</i>leukemia response
Similar Researchers
Based on overlapping research topics